Home › NCT07122986
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RecruitingPhase 1Healthy volunteers welcome
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS
Who can join
Ages 18 to 64 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Ages Eligible for Study: 18 to 64 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Key Inclusion Criteria 1. Adult Participants \>= 18 through \< 64 years of age at the time of enrollment. 2. Healthy participants as determined by medical history, physical examination, and clinical judgement of the investigator to be eligible for inclusion in the study. Key Exclusion Criteria 1. Severe adverse reaction history associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s). 2. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. 3. Women who are pregnant, plan to become pregnant during the study, or are breastfeeding.
About the study
This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults.
What is being tested
- E coli vaccine 1 Dose A (drug)
- E coli vaccine 1 Dose B (drug)
- E coli vaccine 2 (drug)
- E coli vaccine 3 (drug)
- E coli Vaccine 4 Dose A (drug)
- E coli Vaccine 4 Dose B (drug)
Sponsor: Pfizer · Participants: 310 · Started: Aug 11, 2025
Contact the study team
- Pfizer CT.gov Call Center · Phone: 1-800-718-1021
Official record on ClinicalTrials.gov — NCT07122986
Locations in the U.S.
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.